Articles tagged with 'Orsiro Mission' | BIOTRONIK

BIOTRONIK  announced full commercial launch in Canada for its Orsiro® Mission bioabsorbable polymer drug-eluting stent system (BP-DES) indicated for improving coronary luminal diameter in patients including those with diabetes mellitus, with symptoma...

BIOTRONIK announced today it received U.S. Food and Drug Administration (FDA) approval of its Orsiro® Mission bioabsorbable polymer coronary drug-eluting stent system (BP-DES). The company also announced the first US implant and full commercial avail...

According to recently presented TICO trial data, patients with acute coronary syndrome (ACS) treated with BIOTRONIK’s Orsiro® drug eluting stent (DES) benefit from stopping aspirin three months after stenting and continuing only with ticagrelor monot...

BIOTRONIK has announced CE Mark certification for the Orsiro® Mission drug-eluting stent (DES) system. The next generation of the company’s ultrathin strut Orsiro DES provides higher deliverability than other contemporary stents.1 Orsiro Mission is n...